Wamil BD - Search Results

1

Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis.

Fu C, Bardhan S, Cetateanu ND, Wamil BD, Wang Y, Yan HP, Shi E, Carter C, Venkov C, Yakes FM, Page DL, Lloyd RS, Mernaugh RL, Hellerqvist CG. Fu C, et al. Among authors: wamil bd. Clin Cancer Res. 2001 Dec;7(12):4182-94. Clin Cancer Res. 2001. PMID: 11751519

2

Acute inflammatory changes in subcutaneous microtumors in the ears of mice induced by intravenous CM101 (GBS toxin).

Thurman GB, Page DL, Wamil BD, Wilkinson LE, Kasami M, Hellerqvist CG. Thurman GB, et al. Among authors: wamil bd. J Cancer Res Clin Oncol. 1996;122(9):549-53. doi: 10.1007/BF01213551. J Cancer Res Clin Oncol. 1996. PMID: 8781569

3

Phase I study of the antineovascularization drug CM101.

DeVore RF, Hellerqvist CG, Wakefield GB, Wamil BD, Thurman GB, Minton PA, Sundell HW, Yan HP, Carter CE, Wang YF, York GE, Zhang MH, Johnson DH. DeVore RF, et al. Among authors: wamil bd. Clin Cancer Res. 1997 Mar;3(3):365-72. Clin Cancer Res. 1997. PMID: 9815693 Clinical Trial.

4

CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis.

Yakes FM, Wamil BD, Sun F, Yan HP, Carter CE, Hellerqvist CG. Yakes FM, et al. Among authors: wamil bd. Cancer Res. 2000 Oct 15;60(20):5740-6. Cancer Res. 2000. PMID: 11059768

5

Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trail.

Wamil BD, Thurman GB, Sundell HW, DeVore RF, Wakefield G, Johnson DH, Wang YF, Hellerqvist CG. Wamil BD, et al. J Cancer Res Clin Oncol. 1997;123(3):173-9. doi: 10.1007/BF01214670. J Cancer Res Clin Oncol. 1997. PMID: 9119883 Clinical Trial.

6

CM101-mediated recovery of walking ability in adult mice paralyzed by spinal cord injury.

Wamil AW, Wamil BD, Hellerqvist CG. Wamil AW, et al. Among authors: wamil bd. Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13188-93. doi: 10.1073/pnas.95.22.13188. Proc Natl Acad Sci U S A. 1998. PMID: 9789063 Free PMC article.

7

Isolation and identification of the group B streptococcal toxin CM101 from infants with sepsis.

Sundell HW, Yan H, Carter CE, Wamil BD, Wu K, Gaddipati R, Li D, Hellerqvist CG. Sundell HW, et al. Among authors: wamil bd. J Pediatr. 2000 Sep;137(3):338-44. doi: 10.1067/mpd.2000.107839. J Pediatr. 2000. PMID: 10969257

8

CM101 stimulates cutaneous wound healing through an anti-angiogenic mechanism.

Nanney LB, Wamil BD, Whitsitt J, Cardwell NL, Davidson JM, Yan HP, Hellerqvist CG. Nanney LB, et al. Among authors: wamil bd. Angiogenesis. 2001;4(1):61-70. doi: 10.1023/a:1016752925761. Angiogenesis. 2001. PMID: 11824380

9

Functional studies on the anti-pathoangiogenic properties of CM101.

Yan HP, Carter CE, Wang EZ, Page DL, Washington K, Wamil BD, Yakes FM, Thurman GB, Hellerqvist CG. Yan HP, et al. Among authors: wamil bd. Angiogenesis. 1998;2(3):219-33. doi: 10.1023/A:1009258801899. Angiogenesis. 1998. PMID: 14517462

10

Macrophage stimulation using a group B-streptococcus exotoxin (CM101) leads to axonal regrowth in the injured optic nerve.

Ohlsson M, Mattsson P, Wamil BD, Hellerqvist CG, Svensson M. Ohlsson M, et al. Among authors: wamil bd. Restor Neurol Neurosci. 2004;22(1):33-41. Restor Neurol Neurosci. 2004. PMID: 15096692

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Search Page

Filters